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INTRODUCTION
The underlying mechanism for the appearance of motor symptoms in Parkinson disease (PD) has long been identified as a progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc). Motor symptoms appear when 40-60% dopaminergic neurons have died, and when striatal denervation reaches about 80% [1, 2] . Compensating mechanisms are thus needed to delay the onset of motor symptoms which start when they are no longer sufficient to counterbalance striatal dopamine deficiency. In particular, an increase of dopamine turnover has been observed in animal models as well as in PD patients [3] [4] [5] . This increase can be partly explained by an increase in dopamine synthesis through an up-regulation of tyrosine hydroxylase (TH) and aromatic acid decarboxylase (AADC) in the non-affected neurons [6] [7] [8] [9] , as well as a decrease of dopamine uptake by a down-regulation of dopamine transporter (DAT) expression [2, 5] .
The catechol-O-methyl-transferase (COMT) enzyme initiates the degradation of brain synaptic dopamine levels by introducing a methyl-group from S-adenosylmethionin (SAM).
Later, methylated dopamine is further degraded by monoamine oxidase (MAO). The human COMT gene (OMIM 116790) is located on chromosome 22q11.2. and contains two codominant alleles (Val158Met polymorphism, rs4680) which impact the enzyme activity [10] . ) enzymatic activity. COMT activity has been shown to be two-to four-fold higher in the liver and red blood cells of COMT HH subjects than in those with the COMT LL variant [11, 12] . In a previous study, we found an association between the age at onset of motor symptoms in PD and the COMT rs4680, patients carrying COMT HH and COMT HL genotypes showing an earlier age of onset than patients with COMT LL genotypes [13] . These results suggest that COMT activity may be involved in the M A N U S C R I P T
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The level of dopaminergic neuronal degeneration in the substantia nigra pars compacta can be indirectly measured by [123I]-FP-CIT Single Photon Emission Computed Tomography (SPECT).
[123I]-FP-CIT binds to the dopamine transporter, the level of its binding capacity reduction in the striatum reflecting the amount of dopaminergic terminals denervation.
We hypothesized that COMT-activity in the striatum in PD patients contributes to the compensatory mechanisms that impact on clinical severity of motor symptoms in PD. As the extent of this activity is defined by COMT-genotype, we investigated whether, if normalized to motor severity, patients with low COMT-activity would show a higher level of dopaminergic denervation in the striatum measured by [123I]-FP-CIT than patients with high COMTactivity.
METHODS
Subjects and study design
The data in this study was obtained from a clinical trial investigating the effect of subcutaneous injections of bee venom in PD patients (clinicaltrials.gov, NCT01341431).
Clinical and imaging data used in the study were obtained at the screening visit, before randomization and before any therapeutic intervention. Out of 50 patients who were seen for 
Dopamine transporter imaging
SPECT studies were performed in all subjects using a triple-head camera equipped with low 
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7 using a custom [123I]-FP-CIT template [15] . Next, BP was estimated for each parametric image in a standard set of specific volumes of interest (VOI), i.e. right and left caudate nuclei and putamens. These VOI were manually delineated on the MNI single subject MRI by AK in a previous work [15] .
Genotyping
DNA was extracted from peripheral blood lymphocytes using a salting out procedure and stored at −80°C. The rs4680 was analyzed using an a llelic discrimination Taqman assay (ABI PRISM 7900 sequence detection system). The 5' nuclease activity of taq DNA polymerase was used to detect the fluorescent reporter signal generated after the polymerase chain reaction (PCR). As positive controls, two samples of DNA with the COMTHH, COMTHL, and COMTLL genotyped previously confirmed by sequencing were processed concomitantly for each assay. Patients signed a specific informed consent form for the genetic analysis.
Statistics and Analysis
Clinical characteristics were compared between genotypes using the non-parametric Mann- (Figure 1) . By considering the different sub-regions of the striatum, we found similar results for the caudate nucleus (F(1,34)= 8.6, p=0.006, , Figure 1B and Table 2 ) and the putamen (F(1,34)= 7.0, p=0.01, Figure 1C and Table 2 ). Dopaminergic denervation was higher in low and intermediate metabolizers as compared to high metabolizers for both the caudate nucleus and the putamen. The LEDD had no significant effect when introduced as a cofactor in the model.
RESULTS
Patient characteristics
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Other factors associated with dopaminergic denervation
There was a significant independent correlation between BP in the total striatum and clinical motor symptoms (UPDRS III: p=0.04, r=-0.44) ( Table 3 , Figure 2 ). This correlation was significant for both the putamen and the caudate nucleus denervation (r=-0.43, p=0.04, and r=-0.44, p=0.04 respectively). In accordance with previous studies [16] , we also found an independent effect of gender (Table 3 ). In our study, BP in women was 1.59 +/-0.30 as compared to 1.19 +/-0.27 in men (p <0.001). However, there was no significant gendergenotype interaction in our model (p=0.33). with a lower COMT activity, have a greater extent of nigrostriatal denervation than those with a COMT genotype associated with a higher COMT activity (COMT HH ). This result suggests that patients with a lower COMT-activity are able to compensate the neuronal loss to a greater extent by increasing dopamine bioavailability in the striatum.
The Val158Met COMT polymorphism has a functional impact on enzyme activity in the periphery in healthy subjects [12] as well as in PD patients [17, 18] . A PET study recently confirmed that the Val158Met polymorphism also modifies dopamine turnover in the prefrontal cortex in PD patients [19] .. Indeed, this polymorphism has been associated with prefrontal cortex function, such as working memory, in several studies performed in healthy controls [20] as well as in PD [21] . However, the role of the COMT Val158Met polymorphism M A N U S C R I P T
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Indeed, by contrast to the prefrontal cortex, uptake of dopamine by the DAT is the most effective mechanism in the striatum, where the contribution of the COMT remains secondary under normal conditions. Although COMT is expressed in the striatum, inhibition of its activity in rodents either via pharmacological intervention or via disruption of the COMT gene in rodents reveals minor change in their motor behaviour and brain dopamine levels [22] . In accordance with this finding, a study analyzing D2-receptor binding (an indirect measure of endogenous striatal dopamine bio-availability) failed to demonstrate a significant difference between Val158Met genotypes in healthy subjects [20] . However, although COMT deficiency does not alter dopamine concentrations in the striatum, its metabolism is changed as demonstrated by a dramatic increase of DOPAC levels in the dorsal striatum of mice lacking COMT activity [23, 24] . Higher levels of DOPAC in the striatum of patients with the COMTHL+LL genotype could partly explain the motor compensation observed in our study since intracerebral administration of DOPAC in the brain in rats has been shown to cause a modest increase of behavioural activity and stereotypy in rats [25] . A better explanation would be that, in the pathological condition of PD in which dopaminergic terminals degenerate and the DAT expression is dramatically decreased in the striatum, the COMT becomes the major pathway to control dopamine extracellular levels. The effect of the disruption of the COMT gene after dopaminergic denervation has not been studied yet in knockout mice. However, the pharmacological inhibition of DAT in mice lacking COMT resulted in higher dopamine levels in the striatum although this effect increase had little effects on behaviour [23, 26] .
The hypothesis that COMT activity participates in the dopamine bioavailability in the dorsal striatum, is also supported by previous findings showing that PD patients with the COMT HH genotype have an earlier age of disease onset as compared to COMT LL [13] . This result is consistent with our study suggesting that patients with a higher COMT activity (COMT HH ) have lower compensatory capacity than patients with a lower COMT activity (COMT HL+LL ).
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Importantly, this effect is unlikely to be related to a role of the COMT on striatal dopaminergic denervation since no association has been found between the COMT Val158Met polymorphism and PD in the Caucasian population [27] . A potential role of the COMT as a susceptibility factor for PD in patients with other ethnic background, particularly in the Asian population, is still controversial [27, 28] . Another indirect evidence of a potential role of the COMT activity in the striatum is the association that has been found between the low-activity genotype of theVal158Met COMT polymorphism and an increased risk of levodopa-induced dyskinesia in PD [29] .
Interestingly, a gender dimorphism has been found for the Val158Met-polymorphism effect in mice [30] as well as on the age of onset in PD patients [13] which remains to be understood.
In this study, we did not find an interaction between Val158Met COMT polymorphisms and gender for nigrostriatal denervation adjusted on motor severity, but the sample size was too small to properly evaluate this effect.
Our study has some limitations. As PD patients included in this study were more advanced in the course of their disease, this explains the greater extent of dopaminergic denervation in comparison to previous studies in de novo PD patients [31] . In addition, we cannot rule out a residual treatment effect although UPDRS III testing and [123I]-FP-CIT imaging were performed in the OFF-state after a period of washout taking into account the pharmacology of anti-parkinsonian drugs [32] . The robust correlation between motor state (UPDRS part III) and dopamine denervation suggests that the OFF state indeed reflects the motor status of the patients. Our study is also limited by the relative small sample size and will have to be replicated in a larger population of de novo, drug-naïve, PD patients.
CONCLUSION
We showed that genotypes associated with low COMT activity is correlated with a greater extent of nigrostriatal denervation when adjusted to UPDRSIII-score. How COMT activity influences compensatory mechanisms of motor symptoms during the course of PD and whether it influences disease progression remains to be determined. 
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